Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 9/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064647 | 0.94 | KDR (0.48) | KDRFGFR1BRAFRAF1MAPK14 | |
| SCHEMBL5063016 | 0.89 | KDR (0.49) | KDRBRAFRAF1FLT1 | |
| SCHEMBL5068759 | 0.85 | KDR (0.42) | KDRFGFR1BRAFRAF1FLT1 | |
| SCHEMBL3808228 | 0.85 | KDR (0.42) | KDRFGFR1BRAFRAF1FLT1 | |
| SCHEMBL3666384 | 0.84 | KDR (0.47) | KDRFGFR1BRAFRAF1 | |
| SCHEMBL3806605 | 0.83 | KDR (0.48) | KDRFGFR1BRAFRAF1MAPK14 | |
| SCHEMBL5065367 | 0.82 | KDR (0.46) | KDRFGFR1BRAFRAF1MAPK14 | |
| SCHEMBL5060988 | 0.82 | KDR (0.46) | KDRFGFR1BRAFRAF1MAPK14 | |
| SCHEMBL3665084 | 0.81 | KDR (0.46) | KDRFGFR1BRAFRAF1MAPK14 | |
| SCHEMBL3634715 | 0.80 | KDR (0.49) | KDRFGFR1BRAFRAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146718-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131253-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | KDR 263/4885FGFR1 202/4885BRAF 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.